Congratulations to Oregon for passing Measure 109, which will create a program allowing the manufacture, delivery, and administration of psilocybin at supervised, licensed facilities within Oregon. This will be the first program of its kind anywhere in the United States, and perhaps the world. We at Green Light Law Group are extremely excited that patients in Oregon will soon be able to access a possibly revolutionary mental health treatment in a legal, supervised setting.
We also believe that Oregon is the optimum setting for this experiment to take place successfully. As one of the first states to legalize medical and recreational marijuana, the regulatory agencies and legal community here have substantial experience with the rollout and implementation of drug liberalization regimes. Our colleague at Emerge Law Group, Dave Kopilak, is a long-time cannabis lawyer who was one of the drafters of Measure 91 (which legalized recreational cannabis) and was the primary drafter of Measure 109, and the text of Measure 109 bears the imprint of many of the lessons learned during the course of marijuana legalization. For those who have joined us on the rocky road from pre-legal medical marijuana dispensaries to the robust regulatory scheme we currently work within, this should be welcome news.
The first feature of Measure 109 is its two-year development period, which is now set to begin on January 1, 2021, and will end on December 31, 2022. This development period is in place for several reasons, but primarily, it is there because no one has ever worked with state legislators and regulatory agencies to design a therapeutic psychedelics program before now, and there is no sense in rushing through the nuts and bolts of such a program. The development period will give the Oregon Health Authority the time it needs to adopt rules implementing Measure 109, with the advice of the to-be-created Oregon Psilocybin Advisory Board, and will also allow time for any proposed legislative changes to Measure 109 to work their way through in a minimally disruptive fashion.
We will be paying close attention to the findings of the Advisory Board and the input of other stakeholders as this program develops; stay tuned for more.
You can contact Andrew DeWeese at email@example.com or (503) 488-5424.